about
Blockade of IL-36 receptor signaling does not prevent from TNF-induced arthritis.Glycosylation of immunoglobulin G determines osteoclast differentiation and bone lossInduction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentinNeurodegeneration Enhances the Development of Arthritis.Affinity purified anti-citrullinated protein/peptide antibodies target antigens expressed in the rheumatoid joint.Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune diseaseAssociation of a coding polymorphism in Fc gamma receptor 2A and graft survival in re-transplant candidates.Moonlighting osteoclasts as undertakers of apoptotic cells.Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies.The Role of Autoantibodies in Bone Metabolism and Bone Loss.Periarticular Bone Loss in Arthritis Is Induced by Autoantibodies Against Citrullinated Vimentin.[Association between bone catabolism and anti-citrullinated protein antibodies in rheumatoid arthritis].Estrogen induces St6gal1 expression and increases IgG sialylation in mice and patients with rheumatoid arthritis: a potential explanation for the increased risk of rheumatoid arthritis in postmenopausal women.JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast functionThe Role of Dietary Fiber in Rheumatoid Arthritis Patients: A Feasibility StudyHow Autoantibodies Regulate Osteoclast Induced Bone Loss in Rheumatoid ArthritisIgA subclasses have different effector functions associated with distinct glycosylation profilesGeneration and Analysis of Human and Murine OsteoclastsEthanol consumption inhibits TFH cell responses and the development of autoimmune arthritis
P50
Q35222786-67B5C64E-1711-4360-99D7-BFCD44A6CEDAQ35311994-5481CD14-D84D-4F95-8423-BC9CFBA5577EQ35913720-CB01B983-2266-4F20-AB32-B57EE3B283A8Q38966578-31225B8D-B5C6-4415-B4D0-FBEF086DBD88Q39146323-5ACEE508-9F8D-4D38-BDC6-DB25BED954A5Q39251627-AEA99C3F-75DC-4169-A8A9-BB00DA469F97Q40475201-057D78D4-C783-45D9-A8F0-3BFE1C790C8BQ43623184-94D81908-031B-4F0E-A544-19DC8D342306Q44122281-F6994BEA-CB4C-442F-A5B1-31A249B3B1ECQ47331159-12CE1B6B-EE5E-499B-AE52-5900532C96E1Q51046203-F582F1F0-CA46-4680-AA4E-FC892E79DEFAQ53057615-B9CE897A-F777-4EA5-B98B-E81D522CC618Q55395226-6126525D-FAB8-46F7-863A-3C2FB691CF01Q89685433-AFBB9639-47E5-4982-935D-8E46FC32E066Q90574549-793BD25C-79A5-46F1-9C30-14ABA28C75BCQ92106772-A160D8C9-1D8E-499F-BA46-DDA2C973EC0CQ92491366-5EF43A84-8F4E-4EE4-AEEA-6B0461B6048AQ92922048-480CD32F-B74C-41DD-9D2A-360AA214E055Q93216342-DC3EF882-7B82-4EB3-B42D-D20581A2224F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ulrike Harre
@ast
Ulrike Harre
@en
Ulrike Harre
@es
Ulrike Harre
@nl
type
label
Ulrike Harre
@ast
Ulrike Harre
@en
Ulrike Harre
@es
Ulrike Harre
@nl
prefLabel
Ulrike Harre
@ast
Ulrike Harre
@en
Ulrike Harre
@es
Ulrike Harre
@nl
P106
P31
P496
0000-0003-2934-3202